Metropolitan Life Insurance CO Bio Atla, Inc. Transaction History

Metropolitan Life Insurance CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$2.83 - $3.87 $7,324 - $10,015	2,588 New	2,588 $7,000
Q1 2022 May 12, 2022	SELL	$4.38 - $18.78 $17,428 - $74,725	-3,979 Closed	0 $0
Q4 2021 Jun 21, 2023	BUY	$19.0 - $30.95 $75,601 - $123,150	3,979 New	3,979 $78,000
Q3 2021 Jun 21, 2023	BUY	$29.44 - $43.74 $117,141 - $174,041	3,979 New	3,979 $117,000
Q3 2021 Mar 30, 2023	BUY	$29.44 - $43.74 $12,247 - $18,195	416 Added 11.68%	3,979 $117,000
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $12,247 - $18,195	416 Added 11.68%	3,979 $117,000
Q2 2021 Jun 21, 2023	BUY	$38.07 - $56.17 $135,643 - $200,133	3,563 New	3,563 $150,000
Q2 2021 Mar 30, 2023	SELL	$38.07 - $56.17 $2,817 - $4,156	-74 Reduced 2.03%	3,563 $150,000
Q2 2021 Aug 16, 2021	BUY	$38.07 - $56.17 $135,491 - $199,909	3,559 Added 88975.0%	3,563 $151,000
Q1 2021 Jun 26, 2023	BUY	$32.41 - $70.91 $117,875 - $257,899	3,637 New	3,637 $185 Million
Q1 2021 Mar 30, 2023	BUY	$32.41 - $70.91 $117,875 - $257,899	3,637 New	3,637 $184,000
Q1 2021 May 14, 2021	BUY	$32.41 - $70.91 $129 - $283	4 New	4 $185,000

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $54.8M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.